- Quest Diagnostics‘ adjusted EPS for Q4 was $2.23, surpassing estimates of $2.18.
- Reported EPS for the quarter came in at $1.95.
- Net revenue reached $2.62 billion, beating the estimate of $2.57 billion.
- Adjusted operating profit stood at $409 million, higher than the estimated $391.1 million.
- The company achieved an adjusted operating margin of 15.6%, surpassing the expected 15.2%.
- Capital expenditure amounted to $123 million, exceeding the estimate of $118.6 million.
- Diagnostic Information Services Revenue was $2.56 billion, compared to the estimate of $2.52 billion.
- The forecasted adjusted EPS for 2025 is between $9.55 and $9.80, with the consensus estimate at $9.76.
- Full year 2025 reported diluted EPS is expected to be between $8.34 and $8.59.
- Quest Diagnostics anticipates driving revenue growth of close to 7% for the full year, with approximately 3% from organic growth.
- Analyst recommendations include 12 buys, 8 holds, and 0 sells.
Quest Diagnostics on Smartkarma
On Smartkarma, analysts like Baptista Research are closely monitoring Quest Diagnostics, a company making strategic moves in the medical industry. According to Baptista Research‘s report titled “Quest Diagnostics: Expansion into New Markets through Strategic Acquisitions As A Critical Growth Catalyst! – Major Drivers,” the company showed strong performance in the third quarter, with an 8.5% revenue growth driven by new customer acquisitions and key acquisitions like LifeLabs. This growth strategy aims to expand Quest Diagnostics‘ presence in Canada and the U.S., setting the stage for future success.
Another report by Baptista Research, titled “Quest Diagnostics: Will The Acquisition of Canadian Lab Provider LifeLabs Be A Game Changer? – Major Drivers,” highlights Quest Diagnostics‘ recent financial results as a mixed but positive performance. The company experienced a 2.5% revenue increase, fueled by expanding customer base and advanced diagnostics adoption. With a focus on growth and innovation, Quest Diagnostics continues to position itself for success in the competitive healthcare landscape.
A look at Quest Diagnostics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Quest Diagnostics Incorporated, a company that provides diagnostic testing and services nationwide, has received a mix of Smartkarma Smart Scores for its long-term outlook. With a well-rounded score of 3 in Value, Dividend, and Growth, the company shows promising signs in these key areas. However, its Resilience score of 2 indicates some room for improvement in weathering challenging times. On the bright side, Quest Diagnostics has shown strong Momentum with a score of 4, suggesting positive performance in the market.
Quest Diagnostics operates a national network of laboratories and service centers, offering a range of testing services to support healthcare needs. While the company demonstrates a good overall outlook with potential for growth and value, investors may want to keep an eye on its resilience factor. With a solid foundation in diagnostic testing and services, Quest Diagnostics remains a key player in the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
